Search for: "GENENTECH, INC." Results 181 - 200 of 469
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Nov 2013, 6:17 am
 Hacon, with willingness, a scientific background and no stranger to the Patents Court or the EPO (where he has represented Biogen, Genentech and Novartis), quickly became the heir apparent for the empty post. [read post]
15 Sep 2013, 9:42 pm by Patent Docs
Mylan Pharmaceuticals Inc. 1:13-cv-01532; filed September 4, 2013 in the District Court of Delaware • Plaintiffs: Roche Palo Alto LLC; Genentech Inc. [read post]
29 Aug 2013, 9:49 am by Dennis Crouch
Genentech, Inc., 549 U.S. 118, 127 (2007), the appellate court here retreats at least from more liberal interpretations of that decision. [read post]
20 Aug 2013, 8:01 am
Currently, the guidance (given in Glaxo Group Ltd v Genentech Inc [2008] Bus LR 888) is that a stay should be granted, unless it appears that "the evidence is that some commercial certainty would be achieved at a considerably earlier date in the case of the UK proceedings than in the EPO". [read post]
8 Aug 2013, 5:00 am by Bexis
Genentech, Inc., 2012 WL 956192 (S.D. [read post]
21 Jun 2013, 11:41 am by Gene Quinn
The Supreme Court explained the question presented as follows: In Medlmmune, Inc. v. [read post]
20 Jun 2013, 9:05 am by Lawrence B. Ebert
Cir. 2012), citing KSR, supra at 418-421.Of the use of the term "comprising"Genentech, Inc. v. [read post]
22 May 2013, 8:34 pm by Patent Docs
Genentech, Inc., 549 U.S. 118, 137 (2007), this Court ruled that a patent licensee that believes that its products do not infringe the patent and accordingly are not subject to royalty payments is "not required . . . to break or terminate its . . . license agreement before seeking a declaratory judgment in federal court... [read post]
12 May 2013, 9:02 pm by Patent Docs
• Defendants: Genentech, Inc.; City of Hope Declaratory judgment of invalidity, unenforceability, and noninfringement of of U.S. [read post]
9 May 2013, 6:34 pm by Mary Dwyer
Genentech, Inc., the licensee has the burden to prove that its products do not infringe the patent, or whether (as is the case in all other patent litigation, including other declaratory judgment actions), the patentee must prove infringement. [read post]